Truist analyst Robyn Karnauskas raised the firm’s price target on AbbVie to $180 from $160 and keeps a Buy rating on the shares. The analyst cites growing prescription and share growth trends for Skyrizi and Rinvoq as well as growth in Botox in the aesthetics mark for the target raise. Karnauskas raised her Skyrizi and Rinvoq numbers to better align with AbbVie’s long-term guidance.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ABBV:
- Washington state AG files lawsuits against pharmacy chains over opioid crisis
- AbbVie submits sNDA to FDA for linaclotide
- AbbVie (NYSE:ABBV) Is Exiting Trade Groups for Unknown Reasons
- AbCellera, AbbVie enter strategic collaboration
- Exicure announces termination of collaboration agreements with AbbVie, Ipsen
